Group Iv Gp Lp Column Buys 89,200 Shares of Eikon Therapeutics (NASDAQ:EIKN) Stock

Eikon Therapeutics, Inc. (NASDAQ:EIKN) major shareholder Group Iv Gp Lp Column bought 89,200 shares of the stock in a transaction that occurred on Thursday, September 3rd. The stock was purchased at an average price of $11.56 per share, for a total transaction of $1,031,152.00. Following the completion of the purchase, the insider directly owned 89,200 shares in the company, valued at $1,031,152. The trade was a ∞ increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Major shareholders that own at least 10% of a company’s stock are required to disclose their sales and purchases with the SEC.

Eikon Therapeutics Stock Performance

Shares of NASDAQ:EIKN traded down $0.15 during midday trading on Tuesday, hitting $10.71. The company’s stock had a trading volume of 462,105 shares, compared to its average volume of 382,953. The stock’s 50 day simple moving average is $10.60 and its 200 day simple moving average is $10.92. The stock has a market capitalization of $580.16 million and a price-to-earnings ratio of -2.62. Eikon Therapeutics, Inc. has a fifty-two week low of $7.90 and a fifty-two week high of $17.40.

Eikon Therapeutics (NASDAQ:EIKN) last posted its quarterly earnings data on Thursday, August 13th. The company reported ($1.63) earnings per share for the quarter, missing the consensus estimate of ($1.61) by ($0.02). As a group, analysts anticipate that Eikon Therapeutics, Inc. will post -7.24 EPS for the current year.

Analyst Ratings Changes

A number of analysts have weighed in on EIKN shares. Weiss Ratings raised shares of Eikon Therapeutics from a “sell (e-)” rating to a “sell (e)” rating in a report on Monday, August 3rd. Wedbush cut their price objective on shares of Eikon Therapeutics from $5.00 to $4.00 and set an “underperform” rating for the company in a research report on Friday, August 14th. Finally, Cantor Fitzgerald reiterated an “overweight” rating on shares of Eikon Therapeutics in a research report on Friday, August 21st. Five analysts have rated the stock with a Buy rating, one has assigned a Hold rating and two have assigned a Sell rating to the stock. According to MarketBeat, Eikon Therapeutics has a consensus rating of “Hold” and an average price target of $25.00.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently bought and sold shares of EIKN. Legal & General Group Plc acquired a new position in Eikon Therapeutics in the second quarter valued at about $28,000. California State Teachers Retirement System acquired a new stake in shares of Eikon Therapeutics in the second quarter valued at about $51,000. Citadel Advisors LLC acquired a new stake in shares of Eikon Therapeutics in the 2nd quarter valued at approximately $170,000. Deutsche Bank AG acquired a new stake in Eikon Therapeutics in the second quarter valued at $281,000. Finally, The Manufacturers Life Insurance Company grew its holdings in Eikon Therapeutics by 23.5% during the second quarter. The Manufacturers Life Insurance Company now owns 35,357 shares of the company’s stock worth $461,000 after purchasing an additional 6,734 shares during the period.

About Eikon Therapeutics

We are a late-stage clinical biopharmaceutical company dedicated to building a global, fully-integrated organization developing important, innovative medicines to address serious unmet medical needs. We are led by world-renowned drug developers Dr. Roger M. Perlmutter, M.D., Ph.D., and Dr. Roy Baynes, M.D., Ph.D. Our vision is to become a generational leader, by purposefully integrating traditional biology research with advanced engineering to develop better medicines faster. Our initial focus is oncology, where we are advancing a pipeline of drug candidates targeting areas of high unmet need in large indications.